Ultra-thinly traded nano cap BioCardia (OTCQB:BCDA +14.7%) is up on more than double volume, a modest 27K shares, in reaction to its receipt of three new patents for its technologies.
A new U.S. patent (No. 10,520,505) covers the cell potency assay used in its CardiAMP Cell Therapy System.
Patents issued in Japan and China cover its Trillium delivery catheter for transradial arterial access for the intramyocardial delivery of cardiac cell therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.